Four trial volunteers who received Pfizer's COVID-19 vaccine developed Bell's palsy

As the United Kingdom began administering Pfizer-BioNTech vaccine to individuals, Bell's palsy, a form of temporary facial paralysis, was developed by four individuals who obtained Pfizer's coronavirus vaccine in the firm's trial, according to the US regulatory report on the shot.

Regulators from the Food and Drug Administration (FDA) said there was no obvious path for the vaccine to cause Bell's paralysis, but cautioned that the troubling side effect should be watched by physicians and Pfizer should continue to keep track of how many people it strikes.

Bell’s palsy is a condition that causes temporary weakness or paralysis of the facial muscles. It can usually occur when a nerve that controls the muscles becomes inflamed, swollen or compressed.

Meanwhile, Pfizer chief executive Albert Bourla said the company did not "cut any corners" while rolling out the vaccines.

The vaccine has "been tested in the exact same way as we are testing any vaccine that is circulating out there," Bourla asserted, adding, "this vaccine actually was tested, because of the scrutiny, with even higher standards in terms of how we do things."

The Pfizer-BioNTech vaccine comes as coronavirus-related deaths continue to grow worldwide, with more than 1.5 million fatalities and more than 69 million cases.

"Always there are people who are sceptical about vaccines, but I have to say they are wrong," the Pfizer CEO said.

Documents published on Tuesday by U.S. authorities, however, reported that the Pfizer vaccine was highly protective against COVID-19 and appeared healthy, providing the world's first thorough look at the evidence behind the shots.

The Food and Drug Administration's favorable assessment sets the stage for a decision authorizing the initial use of the vaccine within days. Even as across the Atlantic, Britain started vaccinating its eldest people with the shots, which were co-developed with BioNTech, FDA regulators posted their review online.

Article Edited and Republished for CTen by Suraj Maity